Cholesterol Testing Market 2018-2028 By Size, Share, and Forecast

Summary

Report Description

Forecast Period	2024-2028
Market Size (2022)	USD 12.36 Billion
CAGR (2023-2028)	6.92%
Fastest Growing Segment	Test Kits
Largest Market	North America

Market Overview

Global Cholesterol Testing Market has valued at USD 12.36 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 6.92% through 2028. A cholesterol test, also referred to as a lipid profile or lipid panel, is a medical examination that evaluates the levels of different types of cholesterol and fats in your blood. It serves as a crucial diagnostic tool that provides valuable insights into your cardiovascular health. Monitoring and managing cholesterol levels can significantly contribute to the prevention of heart disease and the promotion of overall well-being. It is always advisable to consult with a healthcare professional to comprehend your test results and determine the most appropriate course of action based on your individual health requirements.

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases

Cardiovascular diseases, including heart attacks and strokes, often have subtle or asymptomatic early stages. Cholesterol testing helps identify individuals with high cholesterol levels, who are at an increased risk of developing CVDs. Early detection allows for timely intervention and lifestyle changes that can help prevent or manage the progression of these diseases. Cholesterol testing provides valuable information for risk assessment and stratification. Individuals with elevated cholesterol levels are categorized as high-risk patients for CVDs. This categorization helps healthcare providers tailor treatment and management strategies, potentially preventing future cardiovascular events. For individuals diagnosed with CVDs or at risk of developing them, cholesterol testing is used to monitor the effectiveness of treatments such as medication, dietary changes, and exercise. Regular testing helps healthcare professionals adjust treatment plans as needed to achieve target cholesterol levels. The rising prevalence of cardiovascular diseases underscores the importance of cholesterol testing as a critical tool for prevention, early detection, and management. The increasing demand for cholesterol testing is a natural response to the need to address the growing burden of CVDs and their associated risk factors.

Increase in Demand of Point-of-Care Testing Devices and Home Cholesterol Testing Kits

Point-of-care testing devices and home cholesterol testing kits are playing a significant role in increasing the demand for cholesterol testing. Point-of-care testing devices and home testing kits provide the convenience of immediate testing without the need for a separate visit to a medical facility. This convenience encourages more frequent testing and monitoring, as individuals can easily check their cholesterol levels at home or at a nearby clinic. Rapid results from point-of-care testing and home kits allow individuals to receive immediate feedback on their cholesterol levels. This enables timely intervention, such as lifestyle adjustments or medication adherence, in case of elevated levels. Home testing kits empower individuals to take control of their health by monitoring their cholesterol levels regularly. This increased involvement in their healthcare encourages better management of risk factors and adherence to healthier lifestyles. Some individuals might be more comfortable conducting tests in the privacy of their own homes, which can lead to more accurate results due to reduced anxiety often associated with medical settings. For individuals with established cardiovascular conditions or who are at higher risk due to family history or other factors, point-of-care devices and home testing kits offer a convenient way to monitor their cholesterol levels regularly, supporting ongoing disease management.

Increasing Cases of Obesity

The increasing cases of obesity are a significant driver behind the rising demand for cholesterol testing. Obesity is closely linked to elevated cholesterol levels, especially high levels of LDL cholesterol (often referred to as "bad" cholesterol), which can contribute to the development of cardiovascular diseases (CVDs) and other health complications. Obesity is associated with changes in lipid metabolism, leading to higher levels of triglycerides and LDL cholesterol and lower levels of HDL cholesterol (often referred to as "good" cholesterol). Cholesterol testing helps identify individuals with unfavorable lipid profiles, prompting the need for lifestyle modifications or medical interventions. Obesity is a well-established risk factor for CVDs. Cholesterol testing serves as an essential tool for assessing an individual's cardiovascular risk. Healthcare providers often recommend cholesterol testing for obese individuals to determine their risk level and guide appropriate interventions. Regular cholesterol testing for individuals with obesity can help in the early detection of lipid abnormalities, allowing for timely interventions to prevent or manage cardiovascular risks. This proactive approach can lead to better health outcomes. Many individuals with obesity embark on weight loss and lifestyle modification journeys to improve their health. Cholesterol testing serves as a valuable marker to monitor the effects of these efforts on lipid levels, motivating individuals to stay on track and make necessary adjustments. Healthcare providers often emphasize the importance of cholesterol testing for individuals with obesity to educate them about their cardiovascular risks. This guidance encourages more people to undergo testing as part of their overall health management.

Rising Geriatric Population

The elderly population is more susceptible to cardiovascular diseases and other health issues, leading to a higher demand for cholesterol testing and monitoring among this demographic. As individuals age, their bodies undergo various physiological changes that can impact cholesterol levels. Cholesterol tends to increase naturally with age, and this age-related dyslipidemia can elevate the risk of CVDs. Cholesterol testing becomes crucial for early detection and management of these changes. The elderly is at a greater risk of developing CVDs due to cumulative exposure to risk factors over time. Cholesterol testing helps identify individuals with elevated cholesterol levels, allowing for targeted interventions to manage these risks. Elderly individuals often have multiple chronic conditions, such as diabetes, hypertension, and obesity, which can further elevate their cardiovascular risk. Cholesterol testing assists in managing these complex health profiles. Many elderly individuals are on medications that can impact cholesterol levels, such as statins. Regular cholesterol testing helps healthcare providers monitor the effects of medications and adjust treatment plans as needed. Healthcare for the elderly often emphasizes preventive care to manage the risk of age-related health issues. Cholesterol testing plays a crucial role in identifying potential cardiovascular risks early and guiding preventive measures. For the elderly, lifestyle changes can significantly impact their health and quality of life. Cholesterol testing provides insights into the effectiveness of dietary modifications, exercise regimens, and other lifestyle interventions.

Download Free Sample Report

Key Market Challenges

Technological Limitations

While point-of-care testing devices and home testing kits have improved accessibility, their accuracy might not always match that of laboratory-based testing, potentially affecting diagnostic reliability. Point-of-care testing devices and home testing kits might yield results that can vary from one test to another or from laboratory-based measurements. This variability can lead to uncertainty in interpreting results and making clinical decisions. Home testing kits and point-of-care devices rely on individuals performing the test correctly. User errors, such as improper sample collection or incorrect device operation, can significantly impact the accuracy of results. Proper calibration and maintenance of testing devices are crucial for accuracy. Without regular calibration and quality control, point-of-care devices might drift from accurate results over time. Inaccurate results from point-of-care testing or home testing kits can impact clinical decision-making. Incorrect management strategies based on unreliable results might harm patient outcomes.

Lack of Awareness

Despite increasing awareness, a significant portion of the population may still lack proper understanding of the importance of cholesterol testing. Lack of awareness can lead to delayed or insufficient testing, hindering market growth. Many individuals may underestimate their risk of cardiovascular diseases (CVDs) and fail to recognize that high cholesterol levels can lead to serious health issues. This lack of awareness might prevent them from seeking cholesterol testing in a timely manner. High cholesterol levels typically do not cause noticeable symptoms. As a result, individuals might not recognize the need for testing since they don't feel unwell, leading to a lack of motivation to undergo testing. Misconceptions about cholesterol and its role in heart health can prevent individuals from understanding the value of testing. Some might believe that only older adults need to worry about cholesterol or that they are not at risk due to their age or lifestyle. Routine health check-ups are opportunities for healthcare providers to discuss cholesterol testing with patients. However, if individuals do not schedule regular appointments, they might miss out on these discussions. To overcome this challenge and foster greater awareness about cholesterol testing, public health campaigns, educational initiatives, and patient outreach are crucial. Healthcare providers, medical organizations, and community leaders play a key role in disseminating accurate information about the importance of cholesterol testing and its impact on overall health. Raising awareness through multiple channels, using clear and understandable language, can help increase the demand for cholesterol testing and ultimately contribute to improved cardiovascular health outcomes.

Key Market Trends

Personalized Medicine

The trend toward personalized medicine will likely extend to cardiovascular health. Cholesterol testing can provide essential data for tailoring interventions and treatment plans based on an individual's unique risk profile. The trend toward personalized medicine has the potential to greatly impact cardiovascular health, and cholesterol testing plays a vital role in this shift. Personalized medicine aims to provide individualized healthcare based on an individual's unique genetic makeup, lifestyle, and other factors. Cholesterol testing offers essential data that can help tailor interventions and treatment plans specifically for an individual's risk profile. Based on an individual's cholesterol levels, genetic factors, medical history, and other health metrics, healthcare providers can create personalized treatment plans. This might involve lifestyle modifications, medication choices, and specific targets for cholesterol levels. Personalized medicine involves continuous monitoring of an individual's health markers. Cholesterol testing serves as a valuable tool for tracking progress and ensuring that the chosen interventions are effective. Regular testing encourages patient adherence to treatment plans. For individuals who require cholesterol-lowering medications, personalized medicine can guide the choice of medications and dosages. Certain medications might be more effective or better tolerated based on an individual's genetic and metabolic factors.

Advancements in Testing Technologies

Continued advancements in cholesterol testing technologies, such as improved accuracy of point-of-care devices and home testing kits, can increase their reliability and lead to greater utilization. As technology continues to evolve, improvements in accuracy, convenience, and accessibility can have a significant impact on the cholesterol testing market. Technological innovations can lead to more accurate cholesterol testing results. Improved accuracy builds trust among healthcare providers and patients, increasing confidence in the testing process.

Advanced technologies can incorporate features that minimize errors caused by users during sample collection and test administration. Clear instructions, automated processes, and user-friendly interfaces can improve the reliability of results. Advancements can lead to improvements in the sensitivity and specificity of testing methods, reducing false positives and false negatives, and enhancing the overall accuracy of testing. Miniaturization and Portability: Technologies that allow for smaller, portable testing devices can increase the accessibility of testing, especially in remote or underserved areas. Cholesterol testing technologies can integrate with digital health platforms, enabling real-time data sharing with healthcare providers. This connectivity can improve monitoring, follow-up, and treatment adjustments. Automation of testing processes can reduce human errors and variability, leading to more consistent and accurate results. Future technologies might allow for simultaneous testing of multiple cholesterol parameters, providing a more comprehensive assessment of an individual's lipid profile. Integration of machine learning and artificial intelligence can enhance the accuracy of testing by analyzing complex data patterns and optimizing testing protocols.

Segmental Insights

Test Type Insights

The cholesterol test market is categorized by test type, including total cholesterol test, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides/VLDL cholesterol test. In 2022, the total cholesterol test segment dominated the global market and is expected to maintain this trend throughout the forecast period. This is primarily attributed to the increased awareness of routine cholesterol testing and treatment, as well as the sedentary lifestyle that contributes to the development of various diseases, including diabetes, thereby driving market growth.

Product Type Insights

Based on the type of product, the market is segmented into test kits, test strips, and others. The test kit segment has shown dominance in the global market in 2022 and is expected to maintain its leading position throughout the forecast period. This is primarily attributed to the growing adoption of cholesterol test kits by health-conscious consumers to monitor their cholesterol levels and the availability of cholesterol test kits from various key players in the market. Additionally, excessive alcohol consumption, smoking, consumption of full-fat dairy products, and intake of fatty meat cuts can all contribute to elevated levels of total cholesterol. Consequently, the use of cholesterol kits is encouraged.

Download Free Sample Report

Regional Insights

The cholesterol test market is analyzed across North America, Europe, Asia-Pacific, and South America & MEA. North America accounted for a significant share of the cholesterol test market in 2022 and is expected to maintain its dominance during the forecast period. Key factors driving market growth include the substantial presence of major pharmaceutical and biopharmaceutical companies in North America. Additionally, the rising demand for preventative healthcare is anticipated to further boost market growth. Moreover, increasing government and private sector efforts to promote healthy lifestyles are expected to fuel market expansion in the region throughout the forecast period. The well-established healthcare infrastructure, high purchasing power, and increasing adoption rate of cholesterol test products are also expected to drive market growth. Furthermore, the region's high prevalence of cardiovascular disease and increased awareness about disease prevention contribute to the rising demand for cholesterol tests, thereby further boosting market growth.

Asia-Pacific is expected to exhibit the highest growth rate during the forecast period. This growth can be attributed to the presence of pharmaceutical companies in the region, as well as the increasing purchasing power of populous countries such as China and India. The rise in the geriatric population and the prevalence of cardiovascular diseases such as diabetes are also driving market growth. Additionally, the Asia-Pacific region has a large population base, unmet medical needs, and increasing disposable incomes. The region's growing medical tourism industry and developing healthcare infrastructure make it a lucrative market for cholesterol tests. Asia-Pacific offers profitable opportunities for key players in the cholesterol test industry, registering the fastest growth rate during the forecast period. This is due to the region's growing industrial infrastructure, rising disposable incomes, and the well-established presence of domestic companies. Furthermore, the rise in contract manufacturing organizations in the region provides great opportunities for new entrants. (Note: The original meaning and content of the text have been retained while slightly adjusting the tone to be more professional.

Recent Developments

In May 2022, Goodbody Health proudly unveiled its latest innovation for the UK healthcare industry – the core UK Health “MOT” test. This cutting-edge test includes revolutionary in-clinic diabetes and cholesterol tests that deliver final results within minutes. By evaluating an individual's risk for developing cardiac health problems or diabetes over the next decade, this test contributes to proactive and preventive healthcare.
In March 2022, Rosalind Franklin University’s (RFU) Community Care Connection continued its life-saving mission in partnership with NorthShore University Health System. Through a collaboration empowered by the generous $680,000 financing granted by NorthShore’s Community Investment Fund (CIF), RFU's mobile health unit, known as the Care Coach, provides crucial medical care to underserved individuals in various North Chicago communities. The Care Coach, staffed by licensed healthcare professionals, delivers essential services such as blood pressure control, diabetes screening, BMI assessment, cholesterol testing, and other complementary health treatments.
In 2021, Merck KGaA announced the successful early launch of a new, high-purity synthetic cholesterol product, meeting the surging demand for lipids, a critical component of mRNA-based vaccines and therapeutics. This achievement was accomplished nine months ahead of schedule, demonstrating our commitment to addressing the needs of the industry.
In October 2021, Abcam, Inc., a renowned global leader in life sciences reagents and tools, proudly announced the seamless completion of its acquisition of BioVision. This strategic move has significantly expanded our kits and assays portfolio, bolstering our ability to meet the growing demand of the sector while accelerating the execution of our long-term plan.

Key Market Players

Abbott Laboratories
Beckman Coulter Inc.
Horiba Ltd.
Nova Biomedical
Roche Holding Ag (F.Hoffmann-La Roche Ltd.)
Randox Laboratories Ltd.
Siemens Healthineers Gmbh
Sekisui Diagnostics LLC
Sinocare Inc.
Thermo Fisher Scientific Inc.

By Product Type

By Test Type

By Prescription Mode

By End User

By Region

Test Kits

Test Strips

Other

Total Cholesterol Test

High-Density Lipoprotein (HDL) Cholesterol

Low-Density Lipoprotein (LDL) Cholesterol

Triglycerides/VLDL Cholesterol Test

Over the Counter

Prescription Based

Hospitals & Clinics

Diagnostic Laboratories

Others

North America

Europe

Asia Pacific

South America

Middle East & Africa

Report Scope:

In this report, the Global Cholesterol Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

· Cholesterol Testing Market, By Product Type:

o Test Kits

o Test Strips

o Other

· Cholesterol Testing Market, By Test Type:

o Total Cholesterol Test

o High-Density Lipoprotein (HDL) Cholesterol

o Low-Density Lipoprotein (LDL) Cholesterol

o Triglycerides/VLDL Cholesterol Test

· Cholesterol Testing Market, By Prescription Mode:

o Over the Counter

o Prescription Based

· Cholesterol Testing Market, By End User:

o Hospitals & Clinics

o Diagnostic Laboratories

o Others

· Cholesterol Testing Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia-Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

§ Kuwait

§ Turkey

§ Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cholesterol Testing Market.

Available Customizations:

Global Cholesterol Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Cholesterol Testing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validations

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cholesterol Testing Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Product Type (Test Kits, Test Strips, Others)

5.2.2. By Test Type (Total Cholesterol Test, High-Density Lipoprotein (HDL) Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, Triglycerides/VLDL Cholesterol Test)

5.2.3. By Prescription Mode (Over the Counter, Prescription Based)

5.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)

5.2.5. By Region

5.2.6. By Company (2022)

5.3. Market Map

6. North America Cholesterol Testing Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Product Type

6.2.2. By Test Type

6.2.3. By Prescription Mode

6.2.4. By End User

6.2.5. By Country

6.3. North America: Country Analysis

6.3.1. United States Cholesterol Testing Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Product Type

6.3.1.2.2. By Test Type

6.3.1.2.3. By Prescription Mode

6.3.1.2.4. By End User

6.3.2. Canada Cholesterol Testing Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Product Type

6.3.2.2.2. By Test Type

6.3.2.2.3. By Prescription Mode

6.3.2.2.4. By End User

6.3.3. Mexico Cholesterol Testing Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Product Type

6.3.3.2.2. By Test Type

6.3.3.2.3. By Prescription Mode

6.3.3.2.4. By End User

7. Europe Cholesterol Testing Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Product Type

7.2.2. By Test Type

7.2.3. By Prescription Mode

7.2.4. By End User

7.2.5. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Cholesterol Testing Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Product Type

7.3.1.2.2. By Test Type

7.3.1.2.3. By Prescription Mode

7.3.1.2.4. By End User

7.3.2. United Kingdom Cholesterol Testing Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Product Type

7.3.2.2.2. By Test Type

7.3.2.2.3. By Prescription Mode

7.3.2.2.4. By End User

7.3.3. Italy Cholesterol Testing Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecasty

7.3.3.2.1. By Product Type

7.3.3.2.2. By Test Type

7.3.3.2.3. By Prescription Mode

7.3.3.2.4. By End User

7.3.4. France Cholesterol Testing Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Product Type

7.3.4.2.2. By Test Type

7.3.4.2.3. By Prescription Mode

7.3.4.2.4. By End User

7.3.5. Spain Cholesterol Testing Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Product Type

7.3.5.2.2. By Test Type

7.3.5.2.3. By Prescription Mode

7.3.5.2.4. By End User

8. Asia-Pacific Cholesterol Testing Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Product Type

8.2.2. By Test Type

8.2.3. By Prescription Mode

8.2.4. By End User

8.2.5. By Country

8.3. Asia-Pacific: Country Analysis

8.3.1. China Cholesterol Testing Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Product Type

8.3.1.2.2. By Test Type

8.3.1.2.3. By Prescription Mode

8.3.1.2.4. By End User

8.3.2. India Cholesterol Testing Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Product Type

8.3.2.2.2. By Test Type

8.3.2.2.3. By Prescription Mode

8.3.2.2.4. By End User

8.3.3. Japan Cholesterol Testing Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Product Type

8.3.3.2.2. By Test Type

8.3.3.2.3. By Prescription Mode

8.3.3.2.4. By End User

8.3.4. South Korea Cholesterol Testing Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Product Type

8.3.4.2.2. By Test Type

8.3.4.2.3. By Prescription Mode

8.3.4.2.4. By End User

8.3.5. Australia Cholesterol Testing Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Product Type

8.3.5.2.2. By Test Type

8.3.5.2.3. By Prescription Mode

8.3.5.2.4. By End User

9. South America Cholesterol Testing Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Product Type

9.2.2. By Test Type

9.2.3. By Prescription Mode

9.2.4. By End User

9.2.5. By Country

9.3. South America: Country Analysis

9.3.1. Brazil Cholesterol Testing Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Product Type

9.3.1.2.2. By Test Type

9.3.1.2.3. By Prescription Mode

9.3.1.2.4. By End User

9.3.2. Argentina Cholesterol Testing Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Product Type

9.3.2.2.2. By Test Type

9.3.2.2.3. By Prescription Mode

9.3.2.2.4. By End User

9.3.3. Colombia Cholesterol Testing Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Product Type

9.3.3.2.2. By Test Type

9.3.3.2.3. By Prescription Mode

9.3.3.2.4. By End User

10. Middle East and Africa Cholesterol Testing Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Product Type

10.2.2. By Test Type

10.2.3. By Prescription Mode

10.2.4. By End User

10.2.5. By Country

10.3. MEA: Country Analysis

10.3.1. South Africa Cholesterol Testing Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Product Type

10.3.1.2.2. By Test Type

10.3.1.2.3. By Prescription Mode

10.3.1.2.4. By End User

10.3.2. Saudi Arabia Cholesterol Testing Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Product Type

10.3.2.2.2. By Test Type

10.3.2.2.3. By Prescription Mode

10.3.2.2.4. By End User

10.3.3. UAE Cholesterol Testing Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Product Type

10.3.3.2.2. By Test Type

10.3.3.2.3. By Prescription Mode

10.3.3.2.4. By End User

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development

12.2. Mergers & Acquisitions

12.3. Product Launches

13. Global Oral Clinical Nutrition Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Business Overview

15.2. Service Offerings

15.3. Recent Developments

15.4. Key Personnel

15.5. SWOT Analysis

15.5.1. Abbott Laboratories

15.5.2. Beckman Coulter Inc.

15.5.3. Horiba Ltd.

15.5.4. Nova Biomedical

15.5.5. Roche Holding Ag (F.Hoffmann-La Roche Ltd.)

15.5.6. Randox Laboratories Ltd.

15.5.7. Siemens Healthineers Gmbh

15.5.8. Sekisui Diagnostics LLC

15.5.9. Sinocare Inc.

15.5.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

Figures and Tables

Frequently asked questions

What was the market size of the Global Cholesterol Testing Market in 2022?

The market size of the Global Cholesterol Testing Market was estimated to be USD 12.36 Billion in 2022.

Which was the dominant segment by end user in the Global Cholesterol Testing Market in 2022?

The market is segmented into hospitals, diagnostic centers, and others based on end users. Diagnostic centers held the largest market share in 2022 and are expected to maintain dominance throughout the forecast period. This is attributed to the fact that diagnostic centers perform a wide range of tests to determine the underlying causes of various conditions. Within this category, there are different types of labs, including radiology & MRI centers, imaging centers, and pathology labs. Diagnostic centers are equipped with qualified medical staff capable of addressing health issues, and they also house experienced and skilled radiologists, pathologists, surgeons, and other medical professionals, which further contribute to the growth of this segment.

Which is the dominant region in the Global Cholesterol Testing Market?

North America, encompassing the United States and Canada, dominates the cholesterol test market owing to the high prevalence of lifestyle-related diseases and the adoption of advanced healthcare technologies. Europe holds a significant market share, led by countries such as Germany, the United Kingdom, and France. The region's focus on preventive healthcare, combined with a rapidly aging population, has resulted in a surge in cholesterol screenings. The Asia-Pacific region, including countries like China, Japan, and India, is experiencing rapid market growth due to shifting lifestyles, urbanization, and the adoption of Western diets.

What are the major drivers for the Global Cholesterol Testing Market?

Rise in prevalence of cardiovascular disease, and surge in demand for cholesterol test kits are the major drivers for the Global Cholesterol Testing Market.

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

Cholesterol Testing Market is fueled by Test Kits Segment During the Forecast Period

Nov, 2023

Rising prevalence of cardiovascular diseases and increase in demand of point-of-care testing devices and home cholesterol testing kits is expected to drive the Global Cholesterol Testing Market growt

Buy Now